Lilly Canada welcomes positive recommendation to reimburse Kisunla for early Alzheimer's disease
LLY•Lilly Canada welcomed a positive CDA-AMC recommendation to reimburse Kisunla (donanemab) for early Alzheimer's disease.
1. Reimbursement recommendation
Lilly Canada welcomed a positive CDA-AMC recommendation to reimburse Kisunla (donanemab) for early Alzheimer's disease.
